American Society of Hirudotherapy

Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years

Registry-based randomized controlled trial (extended follow-up) published in Cardiovasc Revasc Med (2024)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialDrug DevelopmentClinical LiteratureOmerovic et al. · Cardiovascular revascularization medicine, 2024

Abstract

BACKGROUND: The registry-based randomized VALIDATE-SWEDEHEART trial (NCT02311231) compared bivalirudin vs. heparin in patients undergoing percutaneous coronary intervention (PCI) for myocardial infarction (MI). It showed no difference in the composite primary endpoint of death, MI, or major bleeding at 180 days. Here, we report outcomes at two years. METHODS: Analysis of primary and secondary endpoints at two years of follow-up was prespecified in the study protocol. We report the study results for the extended follow-up time here. RESULTS: In total, 6006 patients were enrolled, 3005 with ST-segment elevation MI (STEMI) and 3001 with Non-STEMI (NSTEMI), representing 70 % of all eligible patients with these diagnoses during the study. The primary endpoint occurred in 14.0 % (421 of 3004) in the bivalirudin group compared with 14.3 % (429 of 3002) in the heparin group (hazard ratio [HR] 0.97; 95 % confidence interval [CI], 0.85-1.11; P = 0.70) at one year and in 16.7 % (503 of 3004) compared with 17.1 % (514 of 3002), (HR 0.97; 95 % CI, 0.96-1.10; P = 0.66) at two years. The results were consistent in patients with STEMI and NSTEMI and across major subgroups. CONCLUSIONS: Until the two-year follow-up, there were no differences in endpoints between patients with MI undergoing PCI and allocated to bivalirudin compared with those allocated to heparin. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02311231.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleComparative StudyMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov't
Indexed MeSH termsHumansHirudinsHeparinPeptide FragmentsST Elevation Myocardial InfarctionPercutaneous Coronary InterventionRecombinant ProteinsMaleTreatment OutcomeFemaleTime FactorsAgedMiddle AgedAntithrombinsRegistriesAnticoagulantsHemorrhageNon-ST Elevated Myocardial InfarctionRisk FactorsSweden

Summary

In the randomized VALIDATE-SWEDEHEART trial, 6006 myocardial infarction patients undergoing PCI showed no difference between bivalirudin and heparin in death, MI or major bleeding through two years, consistent across STEMI and NSTEMI.

Why This Matters for Hirudotherapy

This registry-based randomized VALIDATE-SWEDEHEART trial enrolled 6006 patients undergoing PCI for STEMI or NSTEMI and found no significant difference between bivalirudin and heparin in the composite primary endpoint of death, MI, or major bleeding at two years (16.7% vs 17.1%; HR 0.97; 95% CI 0.96-1.10; P=0.66), with consistent results across STEMI/NSTEMI subgroups. Bivalirudin is a direct thrombin inhibitor modeled on hirudin, the anticoagulant originally isolated from medicinal leech saliva, so this large trial directly informs the clinical cardiovascular efficacy of a hirudin-derived pharmaceutical relative to standard care. It provides high-quality evidence on how a leech-secretome-inspired anticoagulant performs in a major thrombotic setting, even though the trial found no significant difference between the two rather than superiority. The important caveat is that the study evaluates the synthetic analog bivalirudin, not live hirudotherapy or the broader leech secretome, which contains numerous additional bioactive compounds not assessed in this comparison.

Citation

Reference (Vancouver style)

Omerovic E, James S, Råmundal T, Fröbert O, Linder R, Danielewicz M, et al. Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction-Outcomes at two years. Cardiovasc Revasc Med. 2024;66:43-50. doi:10.1016/j.carrev.2024.03.025. PMID: 38575449

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.